.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The POISE-2 clonidine trial tested whether starting clonidine around the time of noncardiac surgery could reduce perioperative cardiovascular events. The strategy did not reduce the risk of the primary cardiovascular outcome and was associated with clinically important adverse effects, including increased risk of hypotension and nonfatal cardiac arrest. The findings are a useful reminder that aggressive perioperative pharmacologic manipulation is not automatically beneficial. Clonidine can alter sympathetic activity and blood pressure, but perioperative physiology is complex, and medication effects may be harmful when applied broadly without a clear indication. For surgeons and perioperative teams, the practical message is to prioritize evidence-based hemodynamic management and avoid routine prophylactic clonidine for cardiovascular event prevention. Medication decisions should be individualized according to the patient’s baseline treatment, autonomic status, blood-pressure control and operative risk. The trial also reinforces the need to evaluate both efficacy and harm when considering interventions intended to improve surgical outcomes.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The POISE-2 clonidine trial tested whether starting clonidine around the time of noncardiac surgery could reduce perioperative cardiovascular events. The strategy did not reduce the risk of the primary cardiovascular outcome and was associated with clinically important adverse effects, including increased risk of hypotension and nonfatal cardiac arrest. The findings are a useful reminder that aggressive perioperative pharmacologic manipulation is not automatically beneficial. Clonidine can alter sympathetic activity and blood pressure, but perioperative physiology is complex, and medication effects may be harmful when applied broadly without a clear indication. For surgeons and perioperative teams, the practical message is to prioritize evidence-based hemodynamic management and avoid routine prophylactic clonidine for cardiovascular event prevention. Medication decisions should be individualized according to the patient’s baseline treatment, autonomic status, blood-pressure control and operative risk. The trial also reinforces the need to evaluate both efficacy and harm when considering interventions intended to improve surgical outcomes.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
